Skip to main content

Table 3 Summary statistics for clinical outcomes

From: A proof-of-concept study of growth hormone in children with Phelan–McDermid syndrome

Measurea

Variable

Baseline

Mean (SD)

Week 12

Mean (SD)

p value

Wilcoxon r effect

ABC

Irritability

10.31 (7.6)

4.6 (2.3)

0.225

0.50

Social withdrawal

14.8 (7.4)

6.2 (3.4)

0.028

0.90

Stereotypy

8.8 (6.9)

5.1 (1.8)

0.249

0.47

Hyperactivity

33.3 (6.2)

16.5 (7.7)

0.027

0.90

Inappropriate speech

3.3 (4.3)

2.3 (3.8)

0.285

0.44

RBS-R

Stereotyped behavior

4.3 (1.7)

4.0 (2.4)

0.577

0.23

Self-injurious behavior

0.7 (0.8)

1.3 (1.8)

0.157

0.58

Compulsive behavior

2.8 (3.2)

1.3 (1.6)

0.083

0.71

Ritualistic behavior

1.2 (1.2)

0.8 (1.2)

0.414

0.33

Sameness behavior

2.3 (2.4)

2.0 (1.7)

0.680

0.17

Restricted behavior

2.0 (2.2)

1.2 (1.5)

0.129

0.62

Total

13.3 (6.1)

10.7 (3.1)

0.248

0.47

SSP

Tactile

31.5 (2.1)

31.7 (2.0)

1.00

0.00

Taste/smell

18.2 (3.6)

19.4 (1.3)

0.317

0.41

Movement

13.3 (1.6)

13.7 (1.8)

0.157

0.58

Sensation

17.5 (4.8)

20.0 (2.4)

0.416

0.33

Auditory

20.0 (1.9)

22.0 (2.4)

0.144

0.60

Low energy/weak

16.5 (6.9)

20.5 (5.2)

0.141

0.60

Visual/auditory

22.3 (2.3)

22.7 (1.5)

0.414

0.33

Total

139.3

148.8

0.042

0.83

CGI

Improvement score

1.7 (0.5)

0.023

0.93

  1. ABC Aberrant Behavior Checklist, CGI Clinical Global Impressions scale, RBS-R Repetitive Behavior Scales—Revised, SSP Short Sensory Profile
  2. aFor the ABC and RBS-R, lower scores indicate better performance; for the SSP and CGI-Improvement scale, higher scores indicate better performance